论文部分内容阅读
目的观察周剂量多西他赛(DOC)联合奥沙利铂(OXA)方案治疗晚期胃癌的疗效及毒性。方法选择51例晚期胃癌患者,采用DOC 35mg/m2静脉滴注(第1d和第8d);OXA 130mg/m2静脉滴注(第1d),21d为1个周期,2个周期后评价疗效。结果全组51例均可评价疗效,按WHO标准评定近期疗效和毒性,完全缓解4例,部分缓解28例,稳定11例,进展8例,有效率62.7%,中位疾病进展时间为6.7个月,中位生存期为11.9个月。毒性反应主要是骨髓抑制、胃肠道反应和外周神经炎,均为可逆性。结论周剂量DOC联合OXA治疗晚期胃癌疗效确切,毒性反应轻,患者耐受性好,值得临床推广。
Objective To observe the efficacy and toxicity of weekly docetaxel (doc) combined with oxaliplatin (OXA) regimen in the treatment of advanced gastric cancer. Methods Fifty-one patients with advanced gastric cancer were selected and treated with DOC 35 mg / m2 intravenously (day 1 and day 8), intravenous infusion of OXA 130 mg / m2 (day 1), and 1 cycle after 21 days. Results All the 51 cases could evaluate the curative effect. According to the WHO standard, the curative effect and toxicity were evaluated. Four cases were completely relieved, 28 cases partially relieved, 11 cases stable, and 8 cases advanced. The effective rate was 62.7% and the median time to progression was 6.7 Month, the median survival was 11.9 months. Toxicity is mainly myelosuppression, gastrointestinal reactions and peripheral neuritis, are reversible. Conclusion Weekly dosage of DOC combined with OXA in the treatment of advanced gastric cancer has definite curative effect, mild toxic reaction and good patient tolerance. It is worthy of clinical promotion.